Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Clinical Trial Results of the Artificial Pancreas Project, Designed to Provide a Real Solution for Patients with Diabetes, Published Today in the new Issue of the Journal New England Journal of Medicine


News provided by

Schneider Children's Medical Center of Israel

28 Feb, 2013, 12:53 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Prof. Moshe Phillip (Left) with a child connected to the MD-Logic system (PRNewsFoto/Schneider Children's Center)

PETACH TIKVAH, Israel, February 28, 2013 /PRNewswire/ --

The clinical trial was performed in three academic centers: the Schneider Children's Medical Center of Israel, the University Children's Hospital in Slovenia and the Kinderkrankenhaus AUF DER BULT in Germany.

A publication in the February 28th issue of the New England Journal of Medicine reports results of a clinical study with an automated artificial pancreas performed for the first time outside a hospital during a diabetes camp. In a prospective, randomized, multicenter, multinational clinical trial within the DREAM consortium 56  children, adolescents and young adults with insulin dependent type 1 diabetes were treated either with the current state of the art treatment with insulin pumps and glucose sensors or with the MD-Logic artificial pancreas system. The use of the MD-Logic artificial pancreas during the night resulted in significantly fewer events of hypoglycemia and shortened the time patients spent with glucose levels below the normal range as compared to the use of pumps and sensors (control group). Furthermore, the glucose concentration was maintained within the narrow near-normal range for significantly more time with the MD-Logic artificial pancreas as compared to the control without the need of patients' intervention.

     (Photo: http://photos.prnewswire.com/prnh/20130228/600006 )

The clinical trial was performed in three academic centers: Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood diabetes at the Schneider Children's Medical Center of Israel in Petah Tikva, Israel headed by Prof. Moshe Phillip,  the Department of Pediatric Endocrinology, Diabetes and Metabolism headed by Prof. Tadej Battelino at the University Children's Hospital in Ljubljana, Slovenia, and the Department of Pediatric Endocrinology and Diabetes headed by Prof. Thomas Danne & Prof. Olga Kordonouri at the Kinderkrankenhaus AUF DER BULT in Hannover, Germany. Together, the three centers developed the DREAM (Diabetes Wireless Artificial Pancreas Consortium) project aiming at clinical development of the MD-Logic artificial pancreas for routine use by the people with insulin dependent diabetes.

"Night time is a sensitive period of the day during which people with diabetes are not able to consciously control their blood glucose levels and are therefore exposed to extreme fluctuations. Using the MD-Logic artificial pancreas system might change the patients' lives. The results of this study are crucial for further clinical development of a device that could be routinely used as a "Glucositter" at home", says the principal investigator Prof. Moshe Phillip of the Schneider Children's Medical Center of Israel ". Moreover, "the use of the MD-Logic artificial pancreas during the night time may, for the first time, bring some long desired relieve to patients and parents of people with insulin dependent diabetes" adds Prof. Tadej Battelino. "Clinical development of the MD-Logic artificial pancreas system will bring our patients the freedom of a more relaxed lifestyle at no cost to their glucose control" says Prof. Thomas Danne.

Millions of children, adolescents and adults suffer from insulin dependent diabetes which necessitates tight control of blood glucose concentration for preventing acute and long-term complications. Meticulous glycemic control is demanding and requires detailed planning of the diet, physical activity and insulin dosing. The MD-Logic artificial pancreas was developed by the Diabetes Technology Center at the National Center for Childhood Diabetes at Schneider Children's Medical Center of Israel to assist patients with diabetes in achieving the goal of good glycemic control without the burden it usually entails. The multidisciplinary team of doctors, engineers, nurses and dieticians developed the MD-Logic artificial pancreas algorithm which controls routinely available insulin pumps based on the measurements provided by approved subcutaneous continuous glucose sensors. The MD-Logic artificial pancreas algorithm processes the information received from the individual patient, learns her or his specific requirements and based on the glucose concentration commands the minute-to-minute amount of insulin injected into the body.

The National Center for Childhood diabetes at the Schneider Children's Medical Center of Israel cares for around 1600 children, adolescents and young adults with type 1 diabetes with some 150 new patients annually, and performs advanced basic and clinical research in the fields of diabetes and endocrinology. The Department of Pediatric Endocrinology, Diabetes and Metabolism at the University Children's Hospital in Ljubljana, Slovenia is the country's referral center for childhood-onset diabetes, endocrine and metabolic disorders and provides cutting-edge clinical and genetic investigations to these patient populations. The Department of Pediatric Endocrinology and Diabetes at the Kinderkrankenhaus AUF DER BULT in Hannover is the largest pediatric diabetes center in Germany and coordinates the European SWEET initiative to establish reference centers for pediatric diabetes aiming at better quality of care for young patients.

Contact:
Riva Shacked
Spokeperson
Tel: +972-3-9253208
Schneider Children's Medical Center of Israel
rshaked@clalit.org.il
http://www.schneider.org.il/eng

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.